Tissue Repair

Executive Summary

Tissue Repair is a clinical-stage Australian biopharma company developing topical therapies based on its proprietary Glucoprime® yeast-derived beta-glucan, which activates innate immune pathways to accelerate tissue regeneration. The company targets both acute and chronic wound healing, with lead indications in aesthetic aftercare and venous leg ulcers. Its platform leverages a novel mechanism of action that differentiates it from standard care, offering potential for improved healing rates and reduced scarring. With a Phase 3 trial underway for venous leg ulcers, Tissue Repair is approaching a pivotal data readout that could support regulatory filings in Australia and the US. The company's focus on high unmet needs in wound care and its unique immunomodulatory approach position it for significant market opportunity, particularly in the growing diabetic and elderly populations. If successful, Tissue Repair's therapies could become first-in-class treatments for chronic wounds, a market exceeding $15 billion globally. Near-term catalysts include Phase 3 results and potential partnership or licensing deals. The company's strong preclinical and early clinical data suggest a favorable risk-reward profile, though execution on pivotal trials remains critical.

Upcoming Catalysts (preview)

• Q3 2026Phase 3 Topline Data for Venous Leg Ulcers70% success
• Q4 2026Regulatory Submission (NDA) in Australia or US60% success
• Q2 2026Strategic Partnership for Aesthetic Aftercare50% success